Multiple sclerosis (MS) is categorized as an autoimmune disease where T cells attack the central nervous system and cause inflammation in the brain. New evidence shows that the bone marrow is a facilitator that governs the propagation of CNS injury. Autoreactive T cells migrate into the blood marrow and propagate the formation of new autoreactive cells through CXCL12-CXCR4 binding and CCL5-CCR5 axis, which is required for T cells to migrate into the bone marrow. This study indicates that targeting the bone marrow could be a novel therapeutic strategy for the treatment of MS and other autoimmune diseases.
This highly cited CXCR4 antibody (Cat. No. 1009) has been tested in multiple applications, including ELISA, flow cytometry, immunocytochemistry (ICC), immunofluorescence (IF), IHC-P, IP, and western blot. This antibody has also been independently validated, KO, and KD validated.
This CXCR4 antibody (Cat. No. 1012) has also received multiple citations that have been published in the Journal of Virology, Cell, and many more. CXCR4 antibody (Cat. No. 1012) has been tested in multiple applications, including ELISA, immunofluorescence (IF), immunohistochemistry (IHC), and western blot.